Curis Lifesciences Limited (NSE: CURIS) is a Sanand, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹138 Cr, it ranks #2,970 by market cap among the 6,197 Indian listed companies on FinBizNet, and #14 of 26 in Pharmaceutical Contract Manufacturing Services.
| Market Cap | ₹138 Cr |
|---|---|
| NSE Symbol | CURIS |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| Return on Equity | 14.61% |
| Return on Assets | 10.51% |
| 52-Week Range | ₹177.10 – ₹181.00 |
| Headquarters | Sanand, Gujarat |
| Website | curisls.com |
Promoters held 68.03% of Curis Lifesciences Limited's shares as of Mar 2026, unchanged from Nov 2025.
Curis Lifesciences Limited operates as a pharmaceutical manufacturer, specializing in manufacturing of a wide range of pharmaceutical products, such as tablets, capsules, external preparations, oral liquid, and sterile ophthalmic ointments in India. The company's business model operates through loan license manufacturing, through which, the company carry outs manufacturing under Loan License arrangement for domestic suppliers, where all raw materials and excipients are procured and delivered by the client; contract manufacturing, where the company carry outs manufacturing under Contract Manufacturing arrangement for merchant exporters and domestic suppliers, where it would be responsible for procuring and handling all ingredients, raw materials, and packaging materials; and Direct Export/Own Brand Manufacturing, under which the company manufactures products registered by itself in foreign country and sells the said products in foreign country through its distribution. Curis Lifescience
1. Drug Delivery Systems-This segment provides contract manufacturing services for pharmaceutical formulations and products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Drug Delivery Systems-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Curis Lifesciences Limited | ₹138 Cr | — | 14.61% | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Curis Lifesciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Curis Lifesciences Limited has a return on equity of 14.61%.
Curis Lifesciences Limited is listed on the NSE under the symbol CURIS.
Promoters held 68.03% of Curis Lifesciences Limited's shares as of Mar 2026, unchanged from Nov 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.